UNLOCKING
A HIDDEN
UNIVERSE
Decrypting the Dark Proteome,
Delivering Cures.
DECRYPTING THE DARK PROTEOME.
DECRYPTING THE DARK PROTEOME.
RyboDyn is pioneering immunotherapy development by unlocking the dark proteome with our proprietary RyboCypher™ technology. We reveal hidden targets that conventional sequencing overlooks, transforming previously unknown biological signals into breakthrough therapies that redefine patient care.
WHAT IF THE DARK GENOME HELD FAR MORE THAN WE EVER IMAGINED?
OUR DISCOVERIES TO DATE:
For decades, scientists believed that only ~2% of the human genome encoded well-defined, protein-coding genes—merely a fraction of the full picture. At RyboDyn, we asked a bold question: Could the vast, non-coding regions of our genetic code, the dark genome, harbor hidden realms that conventional methods have simply been unable to explore?
Our research shows that this is indeed the case.
WE BUILT THE TOOLS TO DECIPHER NATURE’S HIDDEN CODE
Our revolutionary RyboCypher™ platform fuses novel RNA sequencing with AI models trained on RyboDyn’s proprietary transcriptomic and proteomic databases. By predicting proteins encoded by RNAs once deemed “non-coding,” it turns the dark proteome into a portfolio of therapeutic targets. Engineered to detect insights standard methods never see, RyboCypher™ ignites breakthrough discoveries and powers next-generation immunotherapies.
CRACKING THE DARK CODE
From Dark Targets,
to Breakthrough Therapies
Our pipeline bridges breakthrough science with clinical innovation. Through rigorous validation and meticulous optimization, we transform Dark Targets™ into a robust pipeline of antibody-based drug candidates designed to meet critical unmet needs. As each candidate advances from the lab to clinical development, our commitment remains clear: to deliver first-in-class immunotherapies that revolutionize patient care.
RYBODYN NEWS
PRESS RELEASES & INSIGHTS
